Ken Griffin Biolife Solutions Inc Put Options Transaction History

Citadel Advisors LLC

10 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q4 2024 Feb 14, 2025	BUY	$20.47 - $27.47 $14,329 - $19,229	700 Added 17.5%	4,700 $122,000
Q3 2024 Nov 14, 2024	BUY	$19.19 - $26.52 $61,408 - $84,864	3,200 Added 400.0%	4,000 $100,000
Q2 2024 Aug 14, 2024	SELL	$15.14 - $22.99 $7,570 - $11,495	-500 Reduced 38.46%	800 $17,000
Q1 2024 May 15, 2024	SELL	$15.35 - $18.82 $9,210 - $11,292	-600 Reduced 31.58%	1,300 $24,000
Q4 2023 Feb 14, 2024	BUY	$8.99 - $16.86 $899 - $1,686	100 Added 5.56%	1,900 $30,000
Q3 2023 Nov 14, 2023	SELL	$10.81 - $22.96 $5,405 - $11,480	-500 Reduced 21.74%	1,800 $24,000
Q2 2023 Aug 14, 2023	BUY	$17.19 - $24.34 $12,033 - $17,038	700 Added 43.75%	2,300 $50,000
Q1 2023 May 15, 2023	SELL	$17.67 - $26.07 $42,408 - $62,568	-2,400 Reduced 60.0%	1,600 $34,000
Q4 2022 Feb 14, 2023	SELL	$16.95 - $25.07 $208,485 - $308,361	-12,300 Reduced 75.46%	4,000 $72,000
Q3 2022 Nov 14, 2022	SELL	$14.64 - $26.7 $30,744 - $56,070	-2,100 Reduced 11.41%	16,300 $371,000

188

47.1M

4.3K

4.7K

Ticker BLFS
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 42,684,400
Market Cap $1.21B
Description
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools and services for the cell and gene therapy industry in the United States, Canada, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It of...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.